Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · IEX Real-Time Price · USD
37.89
+0.55 (1.47%)
At close: Apr 26, 2024, 4:00 PM
35.80
-2.09 (-5.52%)
After-hours: Apr 26, 2024, 6:19 PM EDT
Company Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Soleno Therapeutics, Inc.
| Country | United States |
| IPO Date | Nov 13, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Dr. Anish Bhatnagar M.D. |
Contact Details
Address: 203 Redwood Shores Parkway, Suite 500 Redwood City, California 94065 United States | |
| Phone | 650-213-8444 |
| Website | soleno.life |
Stock Details
| Ticker Symbol | SLNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001484565 |
| CUSIP Number | 834203200 |
| ISIN Number | US8342033094 |
| Employer ID | 77-0523891 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anish Bhatnagar M.D. | President, Chief Executive Officer, Chief Operating Officer and Director |
| James H. MacKaness | Chief Financial Officer |
| Patricia C. Hirano | Vice President of Regulatory Affairs |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of Drug Development |
| Meredith Manning M.B.A. | Chief Commercial Officer |
| Kristen Yen M.S. | Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | ARS | Filing |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 22, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 10-K | Annual Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 31, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |